Zemcelpro® distribution agreement announced for Argentina, Hong Kong and Singapore

PartnershipZemcelpro®Positive

AI Analysis

Summary

FarmaMondo has been granted distribution rights for Zemcelpro® (dorocubicel), a European Commission conditionally authorized cell therapy for hematological malignancies, in Argentina, Hong Kong, and Singapore.

Outcome Details

Distribution rights granted for Argentina, Hong Kong and Singapore

Importance:5/10

Sentiment:

0.40

distribution agreementgeographic expansionconditional authorizationUM171 Cell Therapy

Read the original article

Published by PR Newswire Biotech on July 16, 2026 11:00 AM

Read Original